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Introduction
Following the seminal introduction of CMF (cyclo  phos-
phamide, methotrexate, and ﬂ   uorouracil) for adjuvant 
breast cancer treatment more than three decades ago [1], 
the eﬃ     cacy of adjuvant chemo  therapy has gradually 
improved by the introduction of the anthracyclines [2] 
and, more recently, the taxanes [3]. However, while 
anthra  cycline-containing regimens have become stan-
dard treatment for oestrogen receptor (ER)-positive as 
well as ER-negative tumours, conﬂ   icting evidence has 
linked the use of adjuvant taxanes to improved outcome 
in patients with ER-positive tumours. Th  is uncertainty 
has now, to a large extent, been resolved with the results 
from a recent study [4] revealing a beneﬁ  t for ER-positive 
tumours with a high growth rate as evaluated by KI67
status, but no beneﬁ  t for ER-positive tumours with a low 
KI67 score. Th  ese results indicate a way forward; while 
studies three decades ago centred on identifying 
prognostic factors in breast cancer, we are now starting 
to learn predictive factors identifying which tumours 
may achieve optimal beneﬁ  t  from  deﬁ  ned  therapeutic 
regimens [5]. Th  is relates to established drug regimens 
and also to new experimental therapies in parti  cular. 
While this is conventional wisdom with respect to 
targeted therapies, such as endocrine agents and anti-
human epidermal growth factor receptor 2 (anti-HER-2) 
strategies, current data illustrate the need for predictive 
factors to enable optimal use of chemotherapy as well.
Realizing the need to identify predictive factors and, 
ideally, to understand the mechanisms causing drug 
resistance [6], translational research aiming at identifying 
such biological parameters should be part of most phase I 
to III trials [7]. Before discussing future perspectives and 
the implementation of novel drugs, a brief summary of 
the state of the art for predictive factors in breast cancer 
therapy is provided.
Predictive factors in breast cancer treatment
Th   e topic of predictive factors in breast cancer treatment 
has recently been reviewed in detail by Lønning [8]; thus, 
a brief summary will be provided here.
While a slow tumour growth rate, as determined by 
KI67 expression, has been related to a good prognosis in 
patients on endocrine therapy [9], high Ki67 expression, 
as well as high histological grade, has been related to 
improved eﬃ   cacy of chemotherapy, in particular a better 
chance of having a pathological complete response to 
primary systemic treatment [10-13]. With regards to 
other single parameters, TP53 mutations have been 
associated with poor response to anthracycline therapy 
[14,15], but the sensitivity and speciﬁ  city of these do not 
allow their implementation in routine clinical use. HER-2 
ampliﬁ   cation not only predicts eﬃ   cacy  of  anti-HER-2 
therapies but is associated with enhanced eﬃ   cacy  of 
anthracyclines at high doses [16,17], probably due to co-
ampliﬁ   cation of topoisomerase II, an anthracycline 
target, in a subset of tumours [18,19]. Th   e genes for both 
HER-2 and topoisomerase II are located in close 
proximity on chromosome 17. Interestingly, recent data 
have suggested centromere ampliﬁ  cation on this chromo-
some to be a better predictor of anthracycline sensitivity 
compared to ampliﬁ   cation of either HER-2 or 
topoisomerase II [20].
Considering gene expression proﬁ  les, the OncotypeDX 
signature, initially developed as a prognostic signature in 
patients receiving adjuvant tamoxifen treatment [21], has 
been evaluated as a predictive factor with respect to 
chemotherapy eﬃ   cacy. Notably, while a low score by this 
index revealed good prognosis among patients treated 
with tamoxifen but not chemotherapy, a high score 
signalled chemotherapy beneﬁ  ts with CMF [22] as well as 
anthracycline-containing treatment [23]. So far, the 
predictive value of this signature has been evaluated in 
patients harbouring ER-positive tumours exposed to 
tamoxifen; the potential predictive power of the signature 
with respect to the eﬃ   cacy of CMF treatment in ER-
negative tumours has not been addressed. Several of the 
genes included in the signature predict cellular 
proliferation rate; thus, it should be evaluated whether 
the information provided could be reﬂ  ected to the same  © 2010 BioMed Central Ltd
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other supervised signatures, while some have been 
associated with chemotherapy response, they lack the 
sensitivity and speciﬁ  city required for clinical imple  men-
tation (see references in [5]). Moreover, the speciﬁ  city of 
supervised gene expression signatures with respect to 
which genes are included has been challenged [24].
As for the hierarchical gene expression signature 
developed by Perou and colleagues [25,26], tumour 
subclasses are not fully predictive of chemotherapy 
response in either the primary (neoadjuvant) or the 
adjuvant setting [27-29]. While TP53 mutations have a 
tendency to be present in tumours of the HER-2, luminal 
B and basal cell-like classes, they may also be detected 
among tumours belonging to the luminal A class, albeit 
at low incidence [26], underlining the correlation between 
diﬀ   erent parameters but also tumour hetero  geneity, 
probably the main reason why we have been unsuccessful 
in identifying accurate predictive factors. 
Do scientifi  c aims need to be redefi  ned?
Th  e ﬁ   ndings summarized above reveal an emerging 
understanding of the mechanisms controlling tumour 
response to therapy. On the other hand, while some of 
these parameters are used clinically (such as HER-2 
ampliﬁ  cations for anthracycline dose selection), we are 
still far from the goal of ‘individualized medicine’ - the 
selection of optimal therapy at an individual level based 
on predictive factors. To fully achieve such a goal will 
most probably require extension of our ambitions beyond 
identiﬁ   cation of correlative predictive factors toward 
identiﬁ  cation of the mechanisms causing drug resistance.
Th   ere may be several diﬀ  erent entrances into this ﬁ  eld. 
With regard to novel drugs in clinical trials, two 
important examples illustrate unexpected clinical 
observations that may lead translational research into a 
new area, and how new drugs may be designed based on 
molecular translational research identifying molecular 
defects in tumour subgroups.
Th  e ﬁ  rst example relates to novel drugs implemented 
for anti-HER-2 therapy. Th  e tyrosine kinase inhibitor 
lapatinib inhibits HER-1 as well as HER-2 activity, and 
has been shown to have anti-tumour activity in tumours 
resistant to trastuzumab [30]. Surprisingly, among 
patients developing resistance to trastuzumab, lapatinib 
and trastuzumab given together improved progression-
free survival compared to lapatinib monotherapy [31]. 
Such observations deﬁ  ne an ideal clinical setting from 
which tumour samples should be systematically collected 
and analyzed with the aim of identifying the molecular 
mechanisms dictating resistance versus sensitivity to 
these individual compounds.
Th  e second approach - the design of therapeutic 
strategies from knowledge about particular gene defects 
in individual tumours - is illustrated by the development 
of poly ADP ribose polymerase (PARP) inhibitors for 
breast and ovarian cancers in patients harbouring BRCA1 
or  BRCA2 mutations. BRCA1 and BRCA2 mutated 
tumours both have a defect in homologous DNA repair 
[32]. Th   us, phase II studies have shown PARP inhibitors 
to have speciﬁ  c anti-tumour eﬀ  ects in breast as well as 
ovarian carcinomas with BRCA1 and BRCA2 mutations 
[33]. Interestingly, PARP inhibitors were also found to 
enhance eﬃ     cacy of chemotherapy in triple negative 
breast cancers not tested for BRCA1 or BRCA2 mutations 
[35]. Sixty to eighty percent of all triple negative breast 
cancers belong to the so-called basal cell-like class 
[36,37], and about 80% of all breast cancers arising in 
BRCA1 mutation carriers reveal a gene expres  sion proﬁ  le 
resembling basal cell-like tumours [26,38,39]. While only 
10% of all basal-like breast cancers arise in BRCA1 
mutation carriers [40], the similarity with respect to gene 
expression proﬁ   le between spontaneous basal cell-like 
and  BRCA1 mutated tumours has raised the question 
whether basal cell-like tumours may harbour other 
defects in the ‘BRCA1’ pathway [41]. However, the role of 
PARP inhibitors in basal cell-like tumours harbouring 
wild type BRCA1 and BRCA2 remains to be determined; 
in a recent study [42] none of 15 patients with advanced 
triple negative breast cancers responded to a PARP 
inhibitor administered as monotherapy. Currently, we 
lack an explanation for the seeming disparity between the 
studies by Gelmon and colleagues [42] and O’Shaughnessy 
and colleagues [35] with respect to the eﬃ   cacy of PARP 
inhibition in triple negative breast cancer in general. 
Th   ere are several dissimilarities between the studies, one 
evaluating PARP inhibition as monotherapy, the other 
addressing the eﬀ  ect of adding a PARP inhibitor to a 
deﬁ  ned chemotherapy regimen. Finally, the studies used 
diﬀ  erent PARP inhibitors, raising the issue of whether 
these compounds may express additional biological 
eﬀ  ects. Clearly, more data are needed to address this topic.
The way forward
So far, the development of individual predictive factors, 
as well as multigene-expression arrays, has had limited 
impact on therapy. While our aim should be to identify 
the functional mechanisms controlling drug resistance, 
the complexity of the issue should not be underestimated. 
Th  e  ﬁ   nding that nonsense CHEK2 mutations may 
substitute for TP53 mutations as a cause of anthracycline 
resistance [15] is consistent with Chk2 activating p53 in 
response to DNA damage, and suggests a pivotal role of 
this mechanism in eﬀ  ecting anthracycline-induced cell 
death. On the other hand, the p53 protein is subject to 
multiple modiﬁ   cations, including ubiquitinations, de-
acetylations and phosphorylations at multiple sites 
executed by diﬀ  erent enzymes, and may directly interact 
Lønning Breast Cancer Research 2010, 12(Suppl 4):S23
http://breast-cancer-research.com/supplements/12/S4/S23
Page 2 of 4with proteins like MDM2 and MDMX [43]. Th  us, 
activation of diﬀ  erent cellular processes is most likely due 
to multiple factors acting in concert and modulating the 
eﬀ  ects of each other. While substantial evidence suggests 
mutations aﬀ  ecting a limited number of genes may act as 
‘drivers’ of tumour progression [44,45], we do not 
currently know whether similar phenomena relate to 
either primary or acquired drug resistance in vivo. 
Rapidly emerging technologies may allow such analysis 
to be applied to large sets of tumours at reasonable costs 
in the not too distant future [46].
Development of novel techniques for high-throughput 
sequencing opens new possibilities for exploring these 
issues. Th  us, techniques are available for screening the 
whole genome for point mutations as well as indels or 
larger deletions/duplications. Th  us, the ﬁ  rst  reported 
studies of this sort on breast carcinomas have revealed 
substantial inter-tumour diversity with respect to somatic 
alterations [47].
In conclusion, new knowledge and new technologies 
now suggest we should conduct clinical trials diﬀ  erently 
to what we have done over the past decades. Th   e phase I 
to III trial ‘ladder’ remains; however, instead of 
conﬁ  rming marginal beneﬁ  ts in repeated large phase III 
studies, we should concentrate on how we may use these 
new compounds optimally by exploring drug resistance. 
To do so, we not only need tumour tissue bank 
collections, but perhaps more importantly we need to 
design our clinical studies, whenever ethically justiﬁ  able, 
in a way that aims at exploring drug responsiveness in a 
manner that allows systematic comparisons between 
clinical response and biological parameters [48]. Th  e 
examples provided by novel anti-HER-2 strategies as well 
as PARP inhibitors both illustrate ways forward.
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